Arenavirus particles as cancer vaccines
AssigneeHookipa Biotech GmbH
InventorsSarah Schmidt, Klaus Orlinger, Katherine Cohen
Life of this patent
Estimating the term…
Abstract
The present application relates generally to genetically modified arenaviruses that are suitable vaccines against neoplastic diseases, such as cancer. The arenaviruses described herein may be suitable for vaccines and/or treatment of neoplastic diseases and/or for the use in immunotherapies. In particular, provided herein are methods and compositions for treating a neoplastic disease by administering a genetically modified arenavirus in combination with an immune checkpoint inhibitor, wherein the arenavirus has been engineered to include a nucleotide sequence encoding a tumor antigen, tumor associated antigen or antigenic fragment thereof.
Claims26
A method for treating a neoplastic disease in a subject comprising, administering to a subject in need thereof an arenavirus particle and an immune checkpoint inhibitor, wherein said arenavirus particle is engineered to contain an arenavirus genomic segment comprising:
- a nucleotide sequence encoding a tumor antigen, tumor associated antigen or an antigenic fragment thereof;
- and
- (ii) at least one arenavirus open reading frame (“ORF”) in a position other than the wild-type position of said ORF, wherein said ORF encodes the glycoprotein (“GP”), the nucleoprotein (“NP”), the matrix protein Z (“Z protein”) or the RNA dependent RNA polymerase L (“L protein”) of said arenavirus particle, and
- wherein said immune checkpoint inhibitor inhibits, decreases or interferes with the activity of Programmed cell death 1 (PD-1) or Programmed cell death ligand 1 (PD-L1), and
- wherein the tumor antigen or tumor associated antigen is HPV E6 and/or E7 or an antigenic fragment thereof.
A pharmaceutical composition comprising an arenavirus particle, an immune checkpoint inhibitor and a pharmaceutically acceptable carrier, wherein said arenavirus particle is engineered to contain an arenavirus genomic segment comprising:
- a nucleotide sequence encoding a tumor antigen, tumor associated antigen or an antigenic fragment thereof;
- and
- (ii) at least one arenavirus open reading frame (“ORF”) in a position other than the wild-type position of said ORF, wherein said ORF encodes the glycoprotein (“GP”), the nucleoprotein (“NP”), the matrix protein Z (“Z protein”) or the RNA dependent RNA polymerase L (“L protein”) of said arenavirus particle, and
- wherein said immune checkpoint inhibitor inhibits, decreases or interferes with the activity of Programmed cell death 1 (PD-1) or Programmed cell death ligand 1 (PD-L1), and
- wherein the tumor antigen or tumor associated antigen is HPV E6 and/or E7 or an antigenic fragment thereof.
A kit comprising two or more containers and instructions for use, wherein one of said containers comprises an arenavirus particle and another of said containers comprises an immune checkpoint inhibitor, wherein said arenavirus particle is engineered to contain an arenavirus genomic segment comprising:
- a. a nucleotide sequence encoding a tumor antigen, tumor associated antigen or an antigenic fragment thereof;
- and
- b. at least one arenavirus open reading frame (“ORF”) in a position other than the wild-type position of said ORF, wherein said ORF encodes the glycoprotein (“GP”), the nucleoprotein (“NP”), the matrix protein Z (“Z protein”) or the RNA dependent RNA polymerase L (“L protein”) of said arenavirus particle, and
- wherein said immune checkpoint inhibitor inhibits, decreases or interferes with the activity of Programmed cell death 1 (PD-1) or Programmed cell death ligand 1 (PD-L1), and
- wherein the tumor antigen or tumor associated antigen is HPV E6 and/or E7 or an antigenic fragment thereof.
Dependencies are inferred from the claim text.